Testing Zasocitinib in Adults With Active Psoriatic Arthritis
Tests zasocitinib against placebo in adults with active psoriatic arthritis not yet treated with biologics.
Plain-language title generated from the registry record
Registry title: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Key facts
- Where
- Albuquerque, Aventura, Baytown, Bellaire, Boca Raton, Brooklyn, Chandler, Clearwater, Cleveland, Cooper City, Coral Gables, Davie, Denver, Detroit, Fountain Valley, Grand Blanc, Hagerstown, Hialeah, Hickory, Houston, Howell, Jackson, La Mesa, Lake Charles, Lansing, Lubbock, Marietta, Mesquite, Miami, Middleburg Heights, Orland Park, Orlando, Ormond Beach, Phoenix, Plano, Plantation, Saint Clair Shores, Santa Fe, Sarasota, Schaumburg, Spokane, St Louis, Tamarac, Tampa, Thousand Oaks, Tujunga, Whittier, and Wyomissing, United StatesSee the 50 sites
- Phase
- Phase 3
Where in United States
- Albuquerque Center for Rheumatology PCAlbuquerque, United StatesTaking people
- Arthritis & Rheumatic Disease Specialties (AARDS)Aventura, United StatesTaking people
- Accurate Clinical ResearchBaytown, United StatesTaking people
- Novel Research | Bellaire LocationBellaire, United StatesTaking people
- RASF - Clinical Research CenterBoca Raton, United StatesTaking people
- NYU Langone Health | Joseph S. and Diane H. Steinberg Ambulatory Care Center - Rheumatology DepartmentBrooklyn, United StatesTaking people
- AARR- Chandler AZChandler, United StatesTaking people
- Clinical Research of West Florida | Clearwater, FLClearwater, United StatesTaking people
- University Hospitals | UH Cleveland Medical Center - Department of Medicine - Rheumatology DivisionCleveland, United StatesTaking people
- GNP Research, LLC | Hollywood, FLCooper City, United StatesTaking people
- Driven Research LLCCoral Gables, United StatesNo longer taking part
- Tectum Medical ResearchDavie, United StatesTaking people
- Denver Arthritis Clinic | Denver, CODenver, United StatesTaking people
- Henry Ford Health System-Rheumatology DepartmentDetroit, United StatesNo longer taking part
- First Oc Dermatology Research IncFountain Valley, United StatesTaking people
- Michigan Rheumatology Group, P.C. - Grand Blanc OfficeGrand Blanc, United StatesTaking people
- Klein & Associates, M.D., P.A.Hagerstown, United StatesTaking people
- Sweet Hope Research Specialty, Inc, d/b/a Neoclinical ResearchHialeah, United StatesTaking people
- Accellacare of HickoryHickory, United StatesTaking people
- Accurate Clinical ResearchHouston, United StatesTaking people
- Introscience Research | Northwest Houston Arthritis Center - Houston, TXHouston, United StatesTaking people
- Ash Research Clinic - HowellHowell, United StatesTaking people
- West Tennessee Research InstituteJackson, United StatesTaking people
- Purushotham & Akther Kotha MDLa Mesa, United StatesTaking people
- Triwest Research Associates LLCLa Mesa, United StatesTaking people
- Accurate Clinical Research Inc. - Lake CharlesLake Charles, United StatesTaking people
- June DO, PC Private Practice - Dr. Justus FiechtnerLansing, United StatesTaking people
- West Texas Clinical ResearchLubbock, United StatesTaking people
- Marietta Rheumatology AssociatesMarietta, United StatesTaking people
- Southwest Rheumatology Research, LLC | Mesquite, TXMesquite, United StatesTaking people
- Bioresearch PartnersMiami, United StatesTaking people
- Paramount Medical Research & Consulting, LLCMiddleburg Heights, United StatesTaking people
- GSCP/CISOrland Park, United StatesTaking people
- HMD Research, LLCOrlando, United StatesNo longer taking part
- Millennium Research | Ormond Beach, FLOrmond Beach, United StatesTaking people
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZPhoenix, United StatesTaking people
- Clinical Investigations of TexasPlano, United StatesTaking people
- IRIS Research and Development | Plantation, FLPlantation, United StatesTaking people
- Clinical Research Institute of MichiganSaint Clair Shores, United StatesTaking people
- Santa Fe RheumatologySanta Fe, United StatesTaking people
- Sarasota Arthritis Research CenterSarasota, United StatesTaking people
- Greater Chicago Specialty Physicians LLC/CISSchaumburg, United StatesTaking people
- Arthritis Northwest, PLLC | Spokane, WASpokane, United StatesTaking people
- Saint Louis RheumatologySt Louis, United StatesTaking people
- West Broward Rheumatology Associates, Inc.Tamarac, United StatesTaking people
- Clinical Research of West Florida | Tampa, FLTampa, United StatesTaking people
- The Cohen Medical CentersThousand Oaks, United StatesTaking people
- Foothill Arthritis ClinicTujunga, United StatesTaking people
- Medvin Clinical ResearchWhittier, United StatesNo longer taking part
- PA Regional Center for Arthritis and Osteoporosis ResearchWyomissing, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT06671483EU 2024-513111-27-00
- Record updated
- 14 October 2026
- Original description
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).Read full original descriptionShow less
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.
The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Inclusion: Age:; The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is >=19 years of age; Disease Characteristics:; The participant has a diagnosis of PsA; The participant must have signs and symptoms of PsA for at least 3 months prior to screening; The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria); The participant has active arthritis as shown by a minimum of >=3 tender joints in TJC68 and >=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits; The participant has at least 1 active lesion of plaque PsO >=2 cm in diameter, or any nail or nail bed changes characteristic of PsO; Medications for PsA:; The participant has had at least one of the following:; Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID) (not applicable in the European Union [EU]/ European Economic Area [EEA]), OR; Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD).
Exclusion: The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO); The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia; PsA and PsO:.